Literature DB >> 16115125

Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.

Heidi Rye Hudlebusch1, Kim Theilgaard-Mönch, Marianne Lodahl, Hans Erik Johnsen, Thomas Rasmussen.   

Abstract

The frequently detected t(4;14)(p16.3;q32) translocation in multiple myeloma (MM) results in a dysregulation of two potential oncogenes: multiple myeloma SET domain (MMSET) and fibroblast growth factor receptor 3 (FGFR3). As the expression of FGFR3 is undetectable in 30% of the t(4;14)+ MM patients, MMSET has been suggested to play an important role in the malignant transformation associated with the t(4;14) translocation. Screening with a real-time polymerase chain reaction (PCR) found complex expression patterns of the MMSET transcripts in fluorescence-activated cell sorted (FACS)-purified plasma cells (PCs) from 15 t(4;14)+ MM patients. In addition, potential target genes of MMSET type I and II were identified, using microarray analyses of MMSET transfected cell lines. Subsequently, the expression of potential target genes was verified by real-time PCR in FACS-purified PCs from 15 t(4;14)+ and 22 t(4;14)- MM patients. We suggest that the inhibitor of differentiation 1 (ID-1) is a target gene of MMSET, based on its upregulation in MMSET transfected cell lines and a significant association between the t(4;14) translocation and ID-1 expression in MM patients (P = 0.002). As high levels of ID-1 are associated with cancer, our findings indicate that MMSET promotes oncogenic transformation in t(4;14)+ MM patients by transcriptional activation of ID-1 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115125     DOI: 10.1111/j.1365-2141.2005.05664.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Authors:  Deepika Sharma Das; Abhishek Das; Arghya Ray; Yan Song; Mehmet Kemal Samur; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

2.  The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Authors:  Charlotte Pawlyn; Martin F Kaiser; Christoph Heuck; Lorenzo Melchor; Christopher P Wardell; Alex Murison; Shweta S Chavan; David C Johnson; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David A Cairns; Eileen M Boyle; John R Jones; Gordon Cook; Mark T Drayson; Roger G Owen; Walter M Gregory; Graham H Jackson; Bart Barlogie; Faith E Davies; Brian A Walker; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2016-05-27       Impact factor: 12.531

3.  Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma.

Authors:  Peng Zhou; Lie-Lin Wu; Ke-Min Wu; Wei Jiang; Jin-Dong Li; Le-du Zhou; Xin-Ying Li; Shi Chang; Yun Huang; Hui Tan; Ge-Wen Zhang; Feng He; Zhi-Ming Wang
Journal:  Pathol Oncol Res       Date:  2012-12-08       Impact factor: 3.201

4.  The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Authors:  Josh Lauring; Abde M Abukhdeir; Hiroyuki Konishi; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

5.  Wolf-Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation.

Authors:  Chuan Yu; Xiaomin Yao; Linjie Zhao; Ping Wang; Qian Zhang; Chengjian Zhao; Shaohua Yao; Yuquan Wei
Journal:  Neoplasia       Date:  2017-06-24       Impact factor: 5.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.